FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360819985> ?p ?o ?g. }

• W4360819985 endingPage "100508" @default.
• W4360819985 startingPage "100508" @default.
• W4360819985 abstract "IntroductionLorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan.MethodsWe retrospectively analyzed patients with advanced ALK+ NSCLC previously treated with 1L alectinib at multiple sites in Japan. Primary objectives were to collect patient demographics at baseline and estimate time to treatment failure (TTF) with second-line (2L) or third-line (3L) or later line (≥3L) lorlatinib treatment. Secondary objectives included objective response rate (ORR) with lorlatinib, reason for discontinuation and time to last treatment failure with lorlatinib, TTF and ORR of alectinib, and combined TTF.ResultsAmong the 51 patients included in the study, 29 (56.9%) received 2L and 22 (43.1%) received ≥3L lorlatinib treatment. At lorlatinib initiation, brain metastases were reported in 25 patients (49.0%), and 32 (62.7%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Median TTF with lorlatinib was 11.1 months (95% confidence interval [CI]: 4.6–13.8) in any line, 10.8 months (95% CI: 3.9–13.8) in 2L, and 11.5 months (95% CI: 2.9–not reached) in ≥3L. Median TTF was 11.5 months (95% CI: 3.9–not reached) in patients with brain metastases at lorlatinib initiation and 9.9 months (95% CI: 4.3–13.8) in patients without brain metastases. ORR was 35.7% with any-line lorlatinib treatment.ConclusionsPatient characteristics and efficacy were comparable with previous reports when lorlatinib was given after 1L alectinib in patients with ALK+ NSCLC." @default.
• W4360819985 created "2023-03-25" @default.
• W4360819985 creator A5001932083 @default.
• W4360819985 creator A5005471303 @default.
• W4360819985 creator A5007279449 @default.
• W4360819985 creator A5009042976 @default.
• W4360819985 creator A5012645285 @default.
• W4360819985 creator A5014758837 @default.
• W4360819985 creator A5016465101 @default.
• W4360819985 creator A5017499931 @default.
• W4360819985 creator A5020448557 @default.
• W4360819985 creator A5025251965 @default.
• W4360819985 creator A5031431869 @default.
• W4360819985 creator A5033956905 @default.
• W4360819985 creator A5036738616 @default.
• W4360819985 creator A5038101792 @default.
• W4360819985 creator A5047478496 @default.
• W4360819985 creator A5058885400 @default.
• W4360819985 creator A5063817865 @default.
• W4360819985 creator A5070015883 @default.
• W4360819985 creator A5073178976 @default.
• W4360819985 creator A5078287634 @default.
• W4360819985 creator A5079209775 @default.
• W4360819985 creator A5079669844 @default.
• W4360819985 creator A5091073688 @default.
• W4360819985 date "2023-05-01" @default.
• W4360819985 modified "2023-09-27" @default.
• W4360819985 title "A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan" @default.
• W4360819985 cites W2482427906 @default.
• W4360819985 cites W2613260339 @default.
• W4360819985 cites W2624310346 @default.
• W4360819985 cites W2767072667 @default.
• W4360819985 cites W2784414491 @default.
• W4360819985 cites W2899668190 @default.
• W4360819985 cites W2904708360 @default.
• W4360819985 cites W2982198358 @default.
• W4360819985 cites W3043769118 @default.
• W4360819985 cites W3130459803 @default.
• W4360819985 cites W3131623746 @default.
• W4360819985 cites W3182076280 @default.
• W4360819985 cites W3203481850 @default.
• W4360819985 cites W4220815613 @default.
• W4360819985 cites W4225307061 @default.
• W4360819985 cites W4292177899 @default.
• W4360819985 doi "https://doi.org/10.1016/j.jtocrr.2023.100508" @default.
• W4360819985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37250506" @default.
• W4360819985 hasPublicationYear "2023" @default.
• W4360819985 type Work @default.
• W4360819985 citedByCount "1" @default.
• W4360819985 countsByYear W43608199852023 @default.
• W4360819985 crossrefType "journal-article" @default.
• W4360819985 hasAuthorship W4360819985A5001932083 @default.
• W4360819985 hasAuthorship W4360819985A5005471303 @default.
• W4360819985 hasAuthorship W4360819985A5007279449 @default.
• W4360819985 hasAuthorship W4360819985A5009042976 @default.
• W4360819985 hasAuthorship W4360819985A5012645285 @default.
• W4360819985 hasAuthorship W4360819985A5014758837 @default.
• W4360819985 hasAuthorship W4360819985A5016465101 @default.
• W4360819985 hasAuthorship W4360819985A5017499931 @default.
• W4360819985 hasAuthorship W4360819985A5020448557 @default.
• W4360819985 hasAuthorship W4360819985A5025251965 @default.
• W4360819985 hasAuthorship W4360819985A5031431869 @default.
• W4360819985 hasAuthorship W4360819985A5033956905 @default.
• W4360819985 hasAuthorship W4360819985A5036738616 @default.
• W4360819985 hasAuthorship W4360819985A5038101792 @default.
• W4360819985 hasAuthorship W4360819985A5047478496 @default.
• W4360819985 hasAuthorship W4360819985A5058885400 @default.
• W4360819985 hasAuthorship W4360819985A5063817865 @default.
• W4360819985 hasAuthorship W4360819985A5070015883 @default.
• W4360819985 hasAuthorship W4360819985A5073178976 @default.
• W4360819985 hasAuthorship W4360819985A5078287634 @default.
• W4360819985 hasAuthorship W4360819985A5079209775 @default.
• W4360819985 hasAuthorship W4360819985A5079669844 @default.
• W4360819985 hasAuthorship W4360819985A5091073688 @default.
• W4360819985 hasBestOaLocation W43608199851 @default.
• W4360819985 hasConcept C126322002 @default.
• W4360819985 hasConcept C203092338 @default.
• W4360819985 hasConcept C2776232967 @default.
• W4360819985 hasConcept C2778715236 @default.
• W4360819985 hasConcept C2779220645 @default.
• W4360819985 hasConcept C2779422266 @default.
• W4360819985 hasConcept C2779634585 @default.
• W4360819985 hasConcept C3019894029 @default.
• W4360819985 hasConcept C44249647 @default.
• W4360819985 hasConcept C535046627 @default.
• W4360819985 hasConcept C71924100 @default.
• W4360819985 hasConceptScore W4360819985C126322002 @default.
• W4360819985 hasConceptScore W4360819985C203092338 @default.
• W4360819985 hasConceptScore W4360819985C2776232967 @default.
• W4360819985 hasConceptScore W4360819985C2778715236 @default.
• W4360819985 hasConceptScore W4360819985C2779220645 @default.
• W4360819985 hasConceptScore W4360819985C2779422266 @default.
• W4360819985 hasConceptScore W4360819985C2779634585 @default.
• W4360819985 hasConceptScore W4360819985C3019894029 @default.
• W4360819985 hasConceptScore W4360819985C44249647 @default.
• W4360819985 hasConceptScore W4360819985C535046627 @default.
• W4360819985 hasConceptScore W4360819985C71924100 @default.
• W4360819985 hasFunder F4320307765 @default.

• next